Over the past a long time, the number of patients referred for allogeneic hematopoietic mobile transplantation has dropped significantly,133 even so the process must be encouraged to younger/healthy people in whom BCR/BCL2 inhibitor treatment fails, especially in Individuals with TP53aberrations.112 Ultimately, the choice BTK inhibitor acalabrutini